Evidence map›Paper›PMID 26690777›Full record

ArticleMolecular and cellular endocrinology2016

GPER1-mediated IGFBP-1 induction modulates IGF-1-dependent signaling in tamoxifen-treated breast cancer cells.

Ali Vaziri-Gohar, Kevin D Houston

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular and cellular endocrinology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.2field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Investigating differences between tamoxifen resistant and sensitive breast cancer cells with flow cytometry.Cytometry. Part A : the journal of the International Society for Analytical Cytology · 2021
    Article
  7. Review
  8. What turns CREB on? And off? And why does it matter?Cellular and molecular life sciences : CMLS · 2020
    Review
  9. Trop2 Promotes Multidrug Resistance by Regulating Notch1 Signaling Pathway in Gastric Cancer Cells.Medical science monitor : international medical journal of experimental and clinical research · 2020
    Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Ali Vaziri-GoharMolecular Biology Program, New Mexico State University, Las Cruces, NM 88003, USA.
Kevin D HoustonMolecular Biology Program, New Mexico State University, Las Cruces, NM 88003, USA; Department of Chemistry and Biochemistry, New Mexico State University, Las Cruces, NM 88003, USA. Electronic address: khouston@nmsu.edu.
New Mexico State University · US

Funding

NM-INBRE Sequencing and Bioinformatics CoreP20GM103451 · NIGMS · NEW MEXICO STATE UNIVERSITY LAS CRUCES · PI Charlotte C. Gard · 2012 to 2026
$61.2M
NIGMS NIH HHS P20 GM103451NIGMS NIH HHS P20GM103451
6 · The paper itself

Abstract

Tamoxifen, a selective estrogen receptor modulator, is a commonly prescribed adjuvant therapy for estrogen receptor-α (ERα)-positive breast cancer patients. To determine if extracellular factors contribute to the modulation of IGF-1 signaling after tamoxifen treatment, MCF-7 cells were treated with IGF-1 in conditioned medium (CM) obtained from 4-OHT-treated MCF-7 cells and the accumulation of phospho-Akt (S473) was measured. CM inhibited IGF-1-dependent cell signaling and suggesting the involvement of extracellular factors (ie. IGFBPs). A significant increase in IGFBP-1 mRNA and extracellular IGFBP-1 protein was observed in 4-OHT-treated MCF-7 cells. Knockdown experiments demonstrated that both GPER1 and CREB mediate IGFBP-1 induction. Furthermore, experiments showed that 4-OHT-dependent IGFBP-1 transcription is downstream of GPER1-activation in breast cancer cells. Additionally, neutralization and knockdown experiments demonstrated a role for IGFBP-1 in the observed inhibition of IGF-1 signaling. These results suggested that 4-OHT inhibits IGF-1 signaling via GPER1 and CREB mediated extracellular IGFBP-1 accumulation in breast cancer cells.

Indexed as

Breast NeoplasmsCell Culture TechniquesCell Line, TumorCulture Media, ConditionedCyclic AMP Response Element-Binding ProteinFemaleHumansHydroxytestosteronesInsulin-Like Growth Factor Binding Protein 1Insulin-Like Growth Factor IMCF-7 CellsPhosphorylationProto-Oncogene Proteins c-aktReceptors, EstrogenReceptors, G-Protein-CoupledSignal Transduction4,17 beta-dihydroxy-4-androstene-3-oneCREB1 protein, humanCulture Media, ConditionedCyclic AMP Response Element-Binding ProteinGPER1 protein, humanHydroxytestosteronesIGFBP1 protein, humanInsulin-Like Growth Factor Binding Protein 1Insulin-Like Growth Factor IProto-Oncogene Proteins c-aktReceptors, EstrogenReceptors, G-Protein-CoupledTamoxifenBreast cancerGPER1IGF-1IGFBP-1Tamoxifen

Identifiers

PMID26690777
PMCPMC4742395
OpenAlexW2194429659

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.